Lung Dose in Patients Treated With Yttrium-90 for Hepatocellular Carcinoma

Alan Katz56 enrolled

Overview

To Calculate the amount radiation the lung receives in patients receiving Yttrium-90 for Liver Cancer.

To calculate the delivered lung dose using quantitative volumetric analysis in a cohort of patients with unresectable hepatocellular carcinoma who undergo selective internal radiation therapy (SIRT) with Yttrium-90 glass microspheres (TheraSphere®)-and compare this analysis to the lung dose estimated by established criteria. In addition, this study, will summarize the pre and post-treatment clinical data to describe the URMC Y-90 experience.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Liver Neoplasms

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adults ≥ 18 years with no upper limit.-Receiving Y-90 Therasphere liver directed therapy * Pathology proven diagnosis of hepatocellular carcinoma, metastatic colon cancer or other metastatic diseases to be treated with SIRT (Y-90) * surgical resection not feasible at time of initiation of pre-treatment workup -\> 6 months projected life span * ECOG 0-2 Exclusion Criteria: * previous radioembolization of one or more liver lobes or segments without available treatment planning and procedural documentation ie. at another facility prior to URMC Y-90 radioembolization.

Locations (1)

Radiation Oncology, University of Rochester, Medical Center

Rochester, New York, United States

Outcomes

Primary Outcomes

Lung dose measured with actual lung mass vs Lung dose measured with conventional method.

Lung dose measured with actual lung mass vs Lung dose measured with conventional method which assumes 1 kg for all patients. Patient will be receiving this treatment even if not enrolled on this study. The study is NOT about the intervention given to the patient. The study is to determine the best way to measure the radiation dose normal tissue (the lung specifically) receives during this standard treatment.

Time frame: 1 month after treatment.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.